Real world outcomes in patients with lung oligometastases treated with SABR - a single-centre experience
Fatimilehin, Abiola Bewley, Michelle Bowen Jones, Sarah Chan, Clara Coote, Joanna H Harris, Catherine Harris, Maggie A Pemberton, Laura S Salem, Ahmed Sheikh, Hamid Y
Fatimilehin, Abiola
Bewley, Michelle
Bowen Jones, Sarah
Chan, Clara
Coote, Joanna H
Harris, Catherine
Harris, Maggie A
Pemberton, Laura S
Salem, Ahmed
Sheikh, Hamid Y
Citations
Altmetric:
Abstract
Introduction: Delivering Stereotactic Ablative Body Radiotherapy
(SABR) to patients with extracranial oligometastatic disease has the
potential to improve long-term disease control, survival and defer
changes to systemic therapies [1]. We present the results from an
audit of patients treated with SABR under the NHS Commissioning
through Evaluation (CtE) scheme at The Christie Hospital,
Manchester UK.
Methods: The outcomes of patients who received SABR to lung
lesions or thoracic nodes under CtE were analysed. Prescribed doses
included 30-60Gy in 3-8 fractions to nodes and 54-60 Gy in 3-8
fractions to lung lesions. Patients were eligible if aged ≥18, had ≤3
metastatic lesions, WHO performance status of ≤2, onset of
metastatic disease was ≥6 months from the primary tumour
diagnosis and life expectancy estimated to be ≥6 months. The main
outcomes evaluated included local control (assessed by local
radiologists) and overall survival which were obtained from hospital
records. Adverse events by CTCAE grade were recorded prospectively. Results: 52 patients treated between February 2016 and August
2019 were included. Median follow up was 28.5 months and median
age was 72 (range 49-90 years). 51.9% were female and 75% had a
performance status of 0-1. The most common primary was colorectal
(n=23; (44.2%)). 5 patients received SABR to thoracic nodes, and 8
patients had >1 lesion treated. The median BED10 dose was 121 Gy.
Local control was 96% at 1 year and 84.6% at 2 years. Overall survival
was 94.2% at 1 year and 89.7% at 2 years. One patient had a toxicity
graded ≥3, which was fatigue.
Conclusion: The findings demonstrate high levels of local control
and overall survival in these patients, with low rates of toxicity. Our
findings are comparable to the overall national results, and SABR to
oligometastatic lesions has now been commissioned.
Authors
Fatimilehin, Abiola
Bewley, Michelle
Bowen Jones, Sarah
Chan, Clara
Coote, Joanna H
Harris, Catherine
Harris, Maggie A
Pemberton, Laura S
Salem, Ahmed
Sheikh, Hamid Y
Turpin, Zoe
Whitehurst, Philip
Wooder, Rachael
Faivre-Finn, Corinne
Bayman, Neil A
Woolf, David K
Bewley, Michelle
Bowen Jones, Sarah
Chan, Clara
Coote, Joanna H
Harris, Catherine
Harris, Maggie A
Pemberton, Laura S
Salem, Ahmed
Sheikh, Hamid Y
Turpin, Zoe
Whitehurst, Philip
Wooder, Rachael
Faivre-Finn, Corinne
Bayman, Neil A
Woolf, David K
Affiliation
The Christie NHS Foundation Trust, Manchester,
Description
Date
2021
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Fatimilehin A, Bewley M, Bowen Jones S, Chan C, Coote J, Harris C, et al. Real world outcomes in patients with lung oligometastases treated with SABR – a single-centre experience. Lung Cancer . 2021 Jun;156:S58–9.